{
    "root": "5ddf2e09-b083-4ce8-b542-644aadb562e8",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "CYCLOBENZAPRINE HYDROCHLORIDE",
    "value": "20250312",
    "ingredients": [
        {
            "name": "ANHYDROUS LACTOSE",
            "code": "3SY5LH9PMK"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U"
        },
        {
            "name": "CROSPOVIDONE (120 .MU.M)",
            "code": "68401960MK"
        },
        {
            "name": "HYPROMELLOSE, UNSPECIFIED",
            "code": "3NXW29V3WO"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "POLYETHYLENE GLYCOL 400",
            "code": "B697894SGQ"
        },
        {
            "name": "POLYSORBATE 80",
            "code": "6OZP39ZG8H"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "STARCH, CORN",
            "code": "O8232NY3SJ"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "D&C YELLOW NO. 10",
            "code": "35SW5USQ3G"
        },
        {
            "name": "FD&C YELLOW NO. 6",
            "code": "H77VEI93A8"
        },
        {
            "name": "CYCLOBENZAPRINE HYDROCHLORIDE",
            "code": "0VE05JYS2P"
        }
    ],
    "indications": "Cyclobenzaprine hydrochloride tablets, USP are indicated as an adjunct to rest and physical therapy for relief of muscle spasm associated with acute, painful musculoskeletal conditions.\n                  Improvement is manifested by relief of muscle spasm and its associated signs and symptoms, namely, pain, tenderness, limitation of motion, and restriction in activities of daily living.\n                  \n                     Cyclobenzaprine hydrochloride tablets should be used only for short periods (up to 2 or 3 weeks) because adequate evidence of effectiveness for more prolonged use is not available and because muscle spasm associated with acute, painful musculoskeletal conditions is generally of short duration and specific therapy for longer periods is seldom warranted.\n                  \n                  Cyclobenzaprine hydrochloride tablets have not been found effective in the treatment of spasticity associated with cerebral or spinal cord disease, or in children with cerebral palsy.",
    "contraindications": "For most patients, the recommended dose of cyclobenzaprine hydrochloride tablets is 5 mg three times a day. Based on individual patient response, the dose may be increased to 10 mg three times a day. Use of cyclobenzaprine hydrochloride tablets for periods longer than 2 or 3 weeks is not recommended (see              INDICATIONS AND USAGE).           \n                  Less frequent dosing should be considered for hepatically impaired or elderly patients (see              PRECAUTIONS: Impaired Hepatic Function, and Use in the Elderly).",
    "warningsAndPrecautions": "Cyclobenzaprine Hydrochloride Tablets, USP are available containing 5 mg, 7.5 mg or 10 mg of cyclobenzaprine hydrochloride, USP.\n                  The 10 mg tablets are orange-yellow film-coated, round tablets debossed with 022 on one side and plain on other side. They are available as follows:\n                  \n                     \n                         NDC 68788-8474-5\tbottles of 15 tablets\n                     \n                         NDC 68788-84742\tbottles of 20 tablets\n                     \n                         NDC 68788-8474-3\tbottles of 30 tablets\n                     \n                         NDC 68788-8474-6\tbottles of 60 tablets\n                     \n                         NDC 68788-8474-9\tbottles of 90 tablets\n                  \n                  \n                     Store at 20°C to 25°C (68°F to 77°F). [See USP Controlled Room Temperature.]\n                  \n                  Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure.\n                  Distributed by:             \n                     Advagen Pharma Ltd\n                     666 Plainsboro Road             Plainsboro Suite 605,             Plainsboro, NJ, 08536, USA          \n                  Manufactured by:             \n                     Rubicon Research Private Limited,\n                     Ambernath, Dist: Thane,             421506 India             \n                  \n                  Rev: 02, 11/21\n                  \n                     Repackaged By: Preferred Pharmaceuticals Inc.",
    "adverseReactions": "Hypersensitivity to any component of this product.\n                  Concomitant use of monoamine oxidase (MAO) inhibitors or within 14 days after their discontinuation. Hyperpyretic crisis seizures and deaths have occurred in patients receiving cyclobenzaprine (or structurally similar tricyclic antidepressants) concomitantly with MAO inhibitor drugs.\n                  Acute recovery phase of myocardial infarction, and patients with arrhythmias, heart block or conduction disturbances, or congestive heart failure.\n                  Hyperthyroidism."
}